Norditropin

Phase 3Small molecule

Novo Nordisk

Norditropin is one of 107 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

Growth Hormone DeficiencyActive, not recruiting

Noonan SyndromeActive, not recruiting

GrowthActive, not recruiting

Metabolic SyndromePreclinical

Active, not recruiting

Growth Hormone DeficiencyPhase 3

Active, not recruiting

Noonan SyndromePreclinical

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Norditropin

Novo Nordisk

Phase 3

3 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Aricept

Eisai

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

EGRIFTA WR

2 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Treatment

NCT03878446

Q4 2027

Phase 3Active, not recruiting

Children

NCT05330325

Clinical

Trials by Indication[1]

Treatment3 trials

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03811535·200 enrolled

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04970654·110 enrolled

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT03878446·62 enrolled

Growth3 trials

Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.

Completed·UUniversity of Aarhus·N/A·NCT02077348·9 enrolled

Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency

Completed·—·Phase 1/2·NCT03288103·22 enrolled

Luteal Phase Commencing of Growth Hormone

Completed·GGulhane School of Medicine··NCT00561769·61 enrolled

Growth Hormone Deficiency2 trials

Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 2/3·NCT04513171·434 enrolled

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03075644·62 enrolled

Children1 trial

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05330325·412 enrolled

Noonan syndrome1 trial

French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT05308927·221 enrolled

2 more indications

Metabolic Syndrome1 trial

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

Withdrawn·OOregon Health and Science University·N/A·NCT00720616

Unspecified1 trial

Growth Hormone Administration and the Human Immune System

Completed·NNational Institute on Aging (NIA)·Phase 1·NCT00663611·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Norditropin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Norditropin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Norditropin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

Norditropin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Treatment3 trials

Growth3 trials

Growth Hormone Deficiency2 trials

Children1 trial

Noonan syndrome1 trial

Metabolic Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News